Clinical Trial Update: Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Eque-cel in relapsed/refractory multiple myeloma; the study status is NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Eque-cel

Snippet

Sponsor: Nanjing IASO Biotechnology Co., Ltd. | Conditions: Relapsed/Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING